Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET study of AZD4547 in FGFR fusion positive recurrent malignant glioma
2014-005428-81Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fexagratinib in glioma, glioblastoma (GBM) and malignant glioma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-free survival at 6 months (PFS6). Started Jan 2016; status: completed.
02
Drugs
fexagratinib
03
Conditions
gliomaglioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on 2014-005428-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005428-81.